A Propensity Score Matching study on the effect of OnabotulinumtoxinA alone versus Short-Term Psychodynamic Psychotherapy plus drug-of-choice as preventive therapy in Chronic Migraine: effects and predictive factors.
Michele Alessiani(Università Campus Bio-Medico), Vittorio Di Piero(Sapienza University of Rome), Rita De Sanctis(Humanitas University), E Gilliéron(University of Florence), Marta Puma, Alessandro Viganò(Sapienza University of Rome), Barbara Petolicchio(Policlinico Umberto I), Ciro Franzese(IRCCS Humanitas Research Hospital), Romina Di Giambattista(Istituto Psicoanalitico per le Ricerche Sociali)
Cited by 1
Related Papers
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial
|The Lancet Oncology|2017|493
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial
|The Lancet Neurology|2021|260
Functional changes in Duchenne muscular dystrophy
|Neurology|2011|178
PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy
|European Journal of Nuclear Medicine and Molecular Imaging|2019|150